OTCMKTS:NICXF - Nicox Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.15
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Nicox Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NICXF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NICXF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Nicox in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.15.
N/A
The current consensus among 0 investment analysts is to n/a stock in Nicox. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
12/16/2019Cantor FitzgeraldInitiated CoverageOverweight
i
1/31/2019HC WainwrightReiterated RatingBuy
i
Rating by R. Selvaraju at HC Wainwright
(Data available from 4/19/2016 forward)
Nicox logo
Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
Read More

Today's Range

Now: $5.15
$5.15
$5.15

50 Day Range

MA: $5.28
$5.15
$5.54

52 Week Range

Now: $5.15
$4.36
$6.46

Volume

N/A

Average Volume

657 shs

Market Capitalization

$172.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Nicox?

The following sell-side analysts have issued research reports on Nicox in the last year: Zacks Investment Research.
View the latest analyst ratings for NICXF.

What is the current price target for Nicox?

0 Wall Street analysts have set twelve-month price targets for Nicox in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Nicox in the next year.
View the latest price targets for NICXF.

What is the current consensus analyst rating for Nicox?

Nicox currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NICXF.

What other companies compete with Nicox?

How do I contact Nicox's investor relations team?

Nicox's physical mailing address is Drakkar 2 - Batiment D 2405 route des Dolines - CS 10313 Sophia Antipolis Cedex, Valbonne I0, 06560. The company's listed phone number is 33-4-97-24-53-00. The official website for Nicox is www.nicox.com.